Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis Call Transcript - Thomson StreetEvents

Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis Call Transcript

Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis Call Transcript - Thomson StreetEvents
Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis Call Transcript
Published Jun 15, 2023
Published Jun 15, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ALDX.OQ conference call or presentation 15-Jun-23 12:00pm GMT

  
Report Type:

Transcript

Source:
Company:
Aldeyra Therapeutics Inc
Ticker
ALDX.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap Call Transcript – 2024-08-08 – US$ 54.00 – Edited Transcript of ALDX.OQ conference call or presentation 8-Aug-24 1:00pm GMT

Aldeyra Therapeutics Inc Investor Roundtable Transcript – 2024-06-20 – US$ 54.00 – Edited Transcript of ALDX.OQ corporate analyst meeting</ 20-Jun-24 12:00pm GMT

Aldeyra Therapeutics Inc to Discuss the Clinical Development Plan Call Transcript – 2024-03-28 – US$ 54.00 – Edited Transcript of ALDX.OQ conference call or presentation 28-Mar-24 12:00pm GMT

Aldeyra Therapeutics Inc Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 Call Transcript – 2023-06-29 – US$ 54.00 – Edited Transcript of ALDX.OQ conference call or presentation 29-Jun-23 12:00pm GMT

Aldeyra Therapeutics Inc Top-Line Results from the Phase 2 Clinical Trial of ADX-629 in Patients with Chronic Cough Call Transcript – 2023-06-27 – US$ 54.00 – Edited Transcript of ALDX.OQ conference call or presentation 27-Jun-23 12:00pm GMT

Aldeyra Therapeutics Inc at Jefferies Healthcare Conference Transcript – 2023-06-09 – US$ 54.00 – Edited Transcript of ALDX.OQ presentation 9-Jun-23 1:30pm GMT

Aldeyra Therapeutics Inc Q4 2022 Earnings Call Transcript – 2023-03-09 – US$ 54.00 – Edited Transcript of ALDX.OQ earnings conference call or presentation 9-Mar-23 1:00pm GMT

Aldeyra Therapeutics Inc Q3 2022 Earnings Call Transcript – 2022-11-10 – US$ 54.00 – Edited Transcript of ALDX.OQ earnings conference call or presentation 10-Nov-22 1:00pm GMT

Aldeyra Therapeutics Inc to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Call Transcript – 2022-10-06 – US$ 54.00 – Edited Transcript of ALDX.OQ conference call or presentation 6-Oct-22 12:00pm GMT

Aldeyra Therapeutics Inc Q2 2022 Earnings Call Transcript – 2022-08-05 – US$ 54.00 – Edited Transcript of ALDX.OQ earnings conference call or presentation 5-Aug-22 12:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis Call Transcript" Jun 15, 2023. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Aldeyra-Therapeutics-Inc-Top-Line-Results-from-the-Phase-3-INVIGORATE-2-Trial-in-Allergic-Conjunctivitis-Call-T15631985>
  
APA:
Thomson StreetEvents. (2023). Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis Call Transcript Jun 15, 2023. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Aldeyra-Therapeutics-Inc-Top-Line-Results-from-the-Phase-3-INVIGORATE-2-Trial-in-Allergic-Conjunctivitis-Call-T15631985>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.